scispace - formally typeset
G

Gary Middleton

Researcher at University of Birmingham

Publications -  175
Citations -  16508

Gary Middleton is an academic researcher from University of Birmingham. The author has contributed to research in topics: Cancer & Capecitabine. The author has an hindex of 47, co-authored 161 publications receiving 12552 citations. Previous affiliations of Gary Middleton include Royal Surrey County Hospital & University of Cambridge.

Papers
More filters
Journal ArticleDOI

Tracking the Evolution of Non–Small-Cell Lung Cancer

Mariam Jamal-Hanjani, +82 more
TL;DR: Intratumor heterogeneity mediated through chromosome instability was associated with an increased risk of recurrence or death, a finding that supports the potential value of chromosome instability as a prognostic predictor.
Journal ArticleDOI

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
Journal ArticleDOI

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Christopher Abbosh, +119 more
- 25 May 2017 - 
TL;DR: It is shown that phylogenetic ct DNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
Journal ArticleDOI

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Nicholas McGranahan, +219 more
- 30 Nov 2017 - 
TL;DR: It is found that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity.